Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions

Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorR3 Stem Cell

About this trial

To determine the safety and efficacy of Amniotic and Umbilical Cord Tissue for the treatment of the following condition categories: Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions. The hypotheses are that the treatments are not only extremely safe, but also statistically beneficial for all conditions. Outcomes will be determined by numerous valid outcome instruments that compile general quality of life information along with condition-specific information as well.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 18 and over.

Ability to attend follow up visits or at least converse on phone or complete email follow up forms.

Competent to understand the study protocol and provide voluntary informed consent.

Patients with any of the following conditions: Arthritis (Degenerative, Rheumatoid, Psoriatic, Lupus, Gout), Sports or Overuse Injuries (e.g. Rotator Cuff injury, Tennis Elbow), Chronic Kidney Disease (may be on dialysis), Back/Neck Pain, Erectile Dysfunction, Peyronie's Disease, Alzheimer's Disease, Parkinson's Disease, Neuropathy, Post-Stroke, Post-Concussion Syndrome, COPD, Emphysema, Pulmonary Fibrosis, Post myocardial infarction (at least 6 months out), Cardiomyopathy, Congestive Heart Failure.

Disqualifiers

Active Cancer

Pregnancy, Lactating

Severe Clotting disorder

Myocardial Infarction less than six months ago.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Amniotic and Umbilical Cord Tissue Procedure

    Biological/Vaccine

    Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition. Protocols include options for IV, Injection, Intranasal and/or Nebulizer.

Treatment groups

5,000 Participants
are divided into 7 treatment groups

7

Treatment groups

See each treatment group below.

Group A: Amniotic and Umbilical Cord Tissue for Autoimmune ConditionsExperimental treatment 1 intervention
Group B: Amniotic and Umbilical Cord Tissue for Orthopedic ConditionsExperimental treatment 1 intervention
Group C: Amniotic and Umbilical Cord Tissue for Neurologic ConditionsExperimental treatment 1 intervention
Group D: Amniotic and Umbilical Cord Tissue for Urologic ConditionsExperimental treatment 1 intervention
Group E: Amniotic and Umbilical Cord Tissue for Cardiac ConditionsExperimental treatment 1 intervention
Group F: Amniotic and Umbilical Cord Tissue for Renal ConditionsExperimental treatment 1 intervention
Group G: Amniotic and Umbilical Cord Tissue for Pulmonary ConditionsExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Disabilities of Arm, Shoulder, Hand Questionnaire (DASH)

Upper Extremity Outcome Instrument

Time frame
Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
2

Sexual Health Inventory for Men Questionnaire (SHIM)

Erectile Function Questionnaire. Scoring exists from 0 to 25. The lower the score, the more severe the Erectile Dysfunction.

Time frame
Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
3

Kidney Disease and Quality of Life Questionnaire (KDQOL)

Renal Function Outcome Instrument. Raw, precoded numeric values for 36 items are transformed linearly to a 0 to 100 range, with higher scores reflecting better quality of life.

Time frame
Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.
4

Assessment of Quality of Life Questionnaire (AQOL)

General Health Outcome Instrument. Each instrument is used to derive a simple psychometric score for health related quality of life (HRQoL) and to provide profile scores on the different dimensions or items of the descriptive systems. The score is derived by adding the unweighted response order of each question, with a lower score denoting a better quality of life.

Time frame
Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: